Additional Listing

RNS Number : 7325K

Dechra Pharmaceuticals PLC

30 August 2019

 

30 August 2019

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Additional Listing

An application for admission to the Premium Segment of the Official List has been made to the Financial Conduct Authority and the London Stock Exchange for an increase of 133,129 ordinary shares of 1 pence each in relation to the existing block listing (the Shares) for the Company's following schemes:

·      Save As You Earn: 30,000;

·      Long-Term Incentive Scheme: 103,129.

These Shares will rank pari passu with the Company's existing shares in issue.  It is expected that admission will become effective on or around 3 September 2019.

For further information, please contact:

Dechra Pharmaceuticals PLC

Melanie Hall, Company Secretary

Telephone number:  [phone]

Email: [e-mail] 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

ALSLLFSITSIIVIA